first broker upgrade: 5.10, page-6

Without wanting to treat the company too harshly, there has to be some questions asked about their investor/media relations team.

They now have 2 people in the team and they couldnt even crack a mention in the daily papers. If this trial success is as big as they say (which i am sure it is) it is an indictment on them that not one daily paper had even a mention of Australia's first company in many, many years to have taken a drug from research to clinical success all on its own. Very odd.

It also doesnt say much for Australian media's knowledge/interest in the bio-tech community. Maybe PXS have to waste taxpayer money on a synchotron to get noticed. Still Cochlear and CSL used to be well under $10 too!